Navalier picked TEVA as his best emerging market stock for 2010. TEVA is currently the largest generic pharma in the world. As noted earlier, TEVA is ready to kill PFE as soon as Lipitor goes of patent later on this year--and that wasn't even mentioned in his blurb on TEVA.
The cc's aren't that rich, but the appreciation should justify OTM calls.
The stock is at $60.95 and the march 60 puts are at 0.59, if you believe the hype, april 60 puts are at 1.21.
No comments:
Post a Comment